small molecule

DESOWEN

DESONIDE

Loss of exclusivityloss of exclusivity
CompanyGALDERMA LABORATORIES LP

Drug detail

Brand nameDESOWEN
Active ingredientDESONIDE
Strength0.05%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 1984
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DESOWEN patent cliff — loss of exclusivity — | CliffBio